Literature DB >> 1868977

Molecular manipulations of the multidrug transporter: a new role for transgenic mice.

I Pastan1, M C Willingham, M Gottesman.   

Abstract

Multidrug resistance in human cancer is associated with overexpression of the MDR1 gene which encodes a 170,000 molecular weight membrane glycoprotein that transports cytotoxic drugs out of cancer cells. The MDR1 gene is normally expressed in intestine, kidney, liver, and adrenal glands, and in tumors derived from these tissues, but it is not expressed in normal bone marrow. Transgenic mice that express the MDR1 gene in their bone marrow have been developed, and because of this expression these mice are resistant to the bone marrow-suppressive effects of daunomycin, doxorubicin, taxol, and several other anticancer drugs. These mice can be used in several different ways to develop new types of drugs to treat human cancer.--Pastan, I.; Willingham, M. C.; Gottesman, M. Molecular manipulations of the multidrug transporter: a new role for transgenic mice.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1868977     DOI: 10.1096/fasebj.5.11.1868977

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  9 in total

Review 1.  Osmotic opening of the blood-brain barrier: principles, mechanism, and therapeutic applications.

Authors:  S I Rapoport
Journal:  Cell Mol Neurobiol       Date:  2000-04       Impact factor: 5.046

2.  MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy.

Authors:  Andreas-Claudius Hoffmann; Peter Wild; Christina Leicht; Simone Bertz; Kathleen D Danenberg; Peter V Danenberg; Robert Stöhr; Michael Stöckle; Jan Lehmann; Martin Schuler; Arndt Hartmann
Journal:  Neoplasia       Date:  2010-08       Impact factor: 5.715

3.  Current status and future directions of research on multidrug resistance. The impact of contemporary biotechnology.

Authors:  G H Mickisch
Journal:  Urol Res       Date:  1993-03

Review 4.  Functional and molecular characteristics of Na(+)-dependent nucleoside transporters.

Authors:  J Wang; M E Schaner; S Thomassen; S F Su; M Piquette-Miller; K M Giacomini
Journal:  Pharm Res       Date:  1997-11       Impact factor: 4.200

5.  Novobiocin modulates colchicine sensitivity in parental and multidrug-resistant B16 melanoma cells.

Authors:  J Nordenberg; J Kornfeld; L Wasserman; M Shafran; E Halabe; E Beery; O Landau; A Novogrodsky; Y Sidi
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

6.  Increased doxorubicin levels in hepatic tumors with reduced systemic drug exposure achieved with complete hepatic venous isolation and extracorporeal chemofiltration.

Authors:  S A Curley; D L Stone; G M Fuhrman; D C Hohn; Z H Siddik; R A Newman
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 7.  Drug-stimulated ATPase activity of the human P-glycoprotein.

Authors:  G A Scarborough
Journal:  J Bioenerg Biomembr       Date:  1995-02       Impact factor: 2.945

8.  A P-glycoprotein protects Caenorhabditis elegans against natural toxins.

Authors:  A Broeks; H W Janssen; J Calafat; R H Plasterk
Journal:  EMBO J       Date:  1995-05-01       Impact factor: 11.598

Review 9.  Recombinant immunotoxins.

Authors:  I Pastan; L H Pai; U Brinkmann; D FitzGerald
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.624

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.